Quantcast

Industry news that matters to you.  Learn more

Health Care Costs Doubled in Patients Showing Presence of Asthma Biomarker

eMAX Health Systems, LLC announced the results of new research showing almost 200% higher health care costs in patients with elevated peripheral blood eosinophil counts – a key biomarker for severe asthma and asthma exacerbations – compared to those with normal eosinophil counts. This important finding can help identify the high-risk patient with asthma to better manage the disease and reduce costs to the private and government health insurance industry struggling to manage growing asthma costs, estimated to approach $60 billion per year in medical expenses, missed school and work days, and early deaths.

Salivary Cortisol Biomarker May Improve Glucocorticoid Therapy Management

In patients with adrenal insufficiency, salivary cortisol rhythm may serve as a useful biomarker to evaluate the adequacy of glucocorticoid replacement, according to findings from a proof-of-concept study reported in Clinical Endocrinology.

The well-being of patients with adrenal insufficiency depends on optimized glucocorticoid therapy, as undertreatment could induce chronic fatigue and lead to life-threatening adrenal crisis, and overtreatment may have negative, long-term metabolic and cardiovascular consequences, Filippo Ceccato, MD, a doctoral student at the University Hospital of Padova, Italy, and colleagues wrote in the study background.

Singapore Scientists Develop New DNA Technology to Detect Breast Cancer Relapse

Researchers in Singapore, together with international collaborators from Denmark and USA, have successfully identified a unique biomarker that is strongly associated with breast cancer relapse. This finding has led to the development of a simple blood test which has numerous clinical applications, such as detecting relapse early and testing treatment efficacy. The study was recently published in scientific journal Nature Medicine in September 2017.

Invivoscribe Releases LeukoStrat CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit

Invivoscribe® Technologies Inc., a global company with decades of experience providing clonality and biomarker test solutions for the fields of oncology and personalized molecular medicine®, today announces the release of the CE-marked IVD version of its LeukoStrat® CDx FLT3 Mutation Assay which earlier this year was approved by the FDA.

Invivoscribe Receives FDA Approval for the LeukoStrat CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt and is the First Companion Diagnostic for AML

Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® and personalized molecular medicine®, today announces the premarket approval of LeukoStrat® CDx FLT3 Mutation Assay. Due to current labeling for the FDA approved test, FLT3 mutation testing with LeukoStrat® CDx FLT3 Mutation Assay is exclusively performed by The Laboratory for Personalized Molecular Medicine, a subsidiary of Invivoscribe Technologies, Inc., which has gained FDA approval for its FLT3 test as a companion diagnostic for the Novartis drug Rydapt® in newly diagnosed FLT3+ AML.